Results 61 to 70 of about 3,288,590 (262)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane +43 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.
Felix Schlicht +53 more
wiley +1 more source
Humanistic Strategies in the Efl Speaking Class [PDF]
, 2001 This paper focuses on the humanistic strategies woven into the EFL speaking class activities. The speaking class, which the writer used for her study, is the highest level of speaking course offered in the curriculum of the English Department of Petra ...
Mardijono, J. J. (Josefa)
core +1 more source
Cracking the Code: Genotype–Phenotype Correlation Models in Sarcoglycanopathies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Sarcoglycanopathies are among the most severe limb‐girdle muscular dystrophies (LGMD), though milder presentations have been described. These diseases are primarily caused by missense variants, but the limited predictability of their effect on protein maturation, complex formation, and transport has hindered reliable genotype ...
Leonela Luce +72 more
wiley +1 more source
THE PROBLEMS OF LEARNING SPEAKING FACED BY THE FIRST \ud SEMESTER STUDENTS OF STTAD “LEMJIANTEK” MALANG [PDF]
, 2007 In this study, the writer was interested in describing the problems of learning speaking faced by the first semester students of STTAD LEMJIANTEK. Descriptive qualitative research was used as design of this study. The research involved 60 students in the
Wahyu Hidayanti, Desy
core
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source
Elevated Connectivity During Language Processing Is Associated With Cognitive Performance in SeLECTS
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Self‐Limited Epilepsy with Centrotemporal Spikes (SeLECTS) is associated with language impairments despite seizures originating in the motor cortex, suggesting aberrant cross‐network interactions. Here we tested whether functional connectivity in SeLECTS during language tasks predicts language performance.
Wendy Qi +8 more
wiley +1 more source
Latinos and the 2010 Census: The Foreign Born Are More Positive [PDF]
, 2010 Compares survey results on knowledge of, attitudes toward, and participation in the census among foreign- and U.S.-born Latinos/Hispanics and Spanish-speaking, bilingual, and English-speaking Latinos/Hispanics.
Mark Hugo Lopez, Paul Taylor
core
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Intravenous thrombolysis (IVT) before thrombectomy for ischemic stroke may alter clot structure and procedural performance. We investigated how IVT relates to thrombectomy metrics across stroke etiologies. Methods We performed a time‐to‐event analysis of consecutive patients with anterior circulation large vessel occlusion (acLVO ...
Annahita Sedghi +8 more
wiley +1 more source
Speaking with Barry Rovner, MD [PDF]
, 2009 Q: What Alzheimer’s related studies are you involved in currently at the Farber Institute for Neurosciences? Dr. Rovner: We are evaluating three exciting new disease-modifying drug treatments that may slow down the course of Alzheimer’s disease.
core +1 more source